全自动血浆检测作为阿尔茨海默病相关β-淀粉样蛋白状态筛查工具的性能
两项前瞻性多中心横断面研究评估全自动血浆Aβ42、Aβ40及tau等标志物预测脑Aβ状态(以脑脊液Aβ42/Aβ40比值为参照)的准确性。发现队列842人,验证队列237人。血浆Aβ42和Aβ40预测Aβ状态的AUC为0.80,加入APOE基因型后增至0.85,验证队列结果相似。
要点
- 血浆Aβ42和Aβ40可预测各阶段AD的脑Aβ状态,验证队列准确性相似。
- 联合APOE基因型可显著提高预测准确性。
- 在AD试验筛查中可减少PET检查成本达30%至50%。
核心结论
- 全自动血浆Aβ42和Aβ40可预测所有AD阶段的Aβ状态,验证队列准确性相似,联合APOE基因型可进一步提高准确性。
研究设计与样本
- 两项前瞻性、横断面、多中心研究:发现队列来自瑞典BioFINDER研究,连续入组842人(513名认知未受损、265名轻度认知障碍、64名AD痴呆);验证队列来自德国生物标志物研究,入组237人(34名认知未受损、109名轻度认知障碍、94名AD痴呆)。
主要发现
- 发现队列中,血浆Aβ42和Aβ40预测Aβ状态的AUC为0.80(95%CI 0.77-0.83)。
- 加入APOE基因型后AUC显著增至0.85(95%CI 0.82-0.88)。
- 加入血浆tau后AUC为0.86(95%CI 0.83-0.88),再加入NFL后AUC为0.87(95%CI 0.84-0.89)。
- 验证队列中应用发现队列的Aβ42和Aβ40模型,AUC略高为0.86(95%CI 0.81-0.91),但血浆tau无贡献。
- 在AD试验筛查场景中使用血浆Aβ42、Aβ40和APOE,根据截断值不同可减少PET成本达30%至50%。
关键数值与推荐
- 以脑脊液Aβ42/Aβ40比值为脑Aβ状态参照标准。
- 血浆Aβ42、Aβ40和tau采用Elecsys免疫分析法(罗氏诊断)测量。
- 发现队列中血浆Aβ42和Aβ40预测Aβ状态的AUC为0.80(95%CI 0.77-0.83),加入APOE后为0.85(95%CI 0.82-0.88)。
- 验证队列中血浆Aβ42和Aβ40模型的AUC为0.86(95%CI 0.81-0.91)。
临床怎么用
- 血浆Aβ42和Aβ40联合APOE基因型可用于AD临床试验的预筛,降低PET扫描或腰椎穿刺的成本和数量。
- 在临床实践中可作为筛查工具辅助判断脑Aβ状态,但需结合其他评估。
局限性
- 研究为横断面设计,未报告纵向预测性能。
- 验证队列中血浆tau未显示额外贡献,与发现队列不完全一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Accurate blood-based biomarkers for Alzheimer disease (AD) might improve the diagnostic accuracy in primary care, referrals to memory clinics, and screenings for AD trials. OBJECTIVE: To examine the accuracy of plasma β-amyloid (Aβ) and tau measured using fully automated assays together with other blood-based biomarkers to detect cerebral Aβ. DESIGN, SETTING, AND PARTICIPANTS: Two prospective, cross-sectional, multicenter studies. Study participants were consecutively enrolled between July 6, 2009, and February 11, 2015 (cohort 1), and between January 29, 2000, and October 11, 2006 (cohort 2). Data were analyzed in 2018. The first cohort comprised 842 participants (513 cognitively unimpaired [CU], 265 with mild cognitive impairment [MCI], and 64 with AD dementia) from the Swedish BioFINDER study. The validation cohort comprised 237 participants (34 CU, 109 MCI, and 94 AD dementia) from a German biomarker study. MAIN OUTCOME AND MEASURES: The cerebrospinal fluid (CSF) Aβ42/Aβ40 ratio was used as the reference standard for brain Aβ status. Plasma Aβ42, Aβ40 and tau were measured using Elecsys immunoassays (Roche Diagnostics) and examined as predictors of Aβ status in logistic regression models in cohort 1 and replicated in cohort 2. Plasma neurofilament light chain (NFL) and heavy chain (NFH) and APOE genotype were also examined in cohort 1. RESULTS: The mean (SD) age of the 842 participants in cohort 1 was 72 (5.6) years, with a range of 59 to 88 years, and 446 (52.5%) were female. For the 237 in cohort 2, mean (SD) age was 66 (10) years with a range of 23 to 85 years, and 120 (50.6%) were female. In cohort 1, plasma Aβ42 and Aβ40 predicted Aβ status with an area under the receiver operating characteristic curve (AUC) of 0.80 (95% CI, 0.77-0.83). When adding APOE, the AUC increased significantly to 0.85 (95% CI, 0.82-0.88). Slight improvements were seen when adding plasma tau (AUC, 0.86; 95% CI, 0.83-0.88) or tau and NFL (AUC, 0.87; 95% CI, 0.84-0.89) to Aβ42, Aβ40 and APOE. The results were similar in CU and cognitively impaired participants, and in younger and older participants. Applying the plasma Aβ42 and Aβ40 model from cohort 1 in cohort 2 resulted in slightly higher AUC (0.86; 95% CI, 0.81-0.91), but plasma tau did not contribute. Using plasma Aβ42, Aβ40, and APOE in an AD trial screening scenario reduced positron emission tomography costs up to 30% to 50% depending on cutoff. CONCLUSIONS AND RELEVANCE: Plasma Aβ42 and Aβ40 measured using Elecsys immunoassays predict Aβ status in all stages of AD with similar accuracy in a validation cohort. Their accuracy can be further increased by analyzing APOE genotype. Potential future applications of these blood tests include prescreening of Aβ positivity in clinical AD trials to lower the costs and number of positron emission tomography scans or lumbar punctures.
引用
- Palmqvist S, Janelidze S, Stomrud E, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. JAMA Neurol. 2019. PMID: 31233127. doi:10.1001/jamaneurol.2019.1632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。